ACAD Dec 2025 45.000 call
- Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, September 26, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 23, 2024, the Board of Directors granted Catherine Owen Adams, Acadia’s new Chief Executive Officer, a one-time sign-on equity award of (i) 353,261 options to purchase shares of Acadia’s common stock with an exercise price of $16.29 per share, Acadia’s closing trading price on September 23, 2024, which vest 25% on the first anniversary of grant and in equal monthly installments over the th
- Business Wire
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
SAN DIEGO, September 23, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors.
- Simply Wall St.
High Growth Tech Stocks To Watch In September 2024
The market has stayed flat over the past 7 days but has risen 23% in the past 12 months, with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high growth tech stocks that can capitalize on these trends is crucial for investors looking to maximize their returns.
